INTRODUCTION
I was asked to contribute this paper because of an article written, somewhat with tongue in cheek, dissenting from the orthodoxy of evidence-based medicine (EBM)1. This got me into trouble and so I am pleased to be given the opportunity to state my position having thought about the subject and discussed my opinions with colleagues in the field during the last 2 years.
In my own small way during 40 years of clinical practice, I have been trying to combine my clinical expertise with the best available external clinical evidence. I have to say that doing that conscientiously has been and continues to be very difficult. So why am I challenging the new orthodoxy of EBM? COMMON CRITICISMS OF EBM If I say that EBM is 'old hat' and that people are already doing it, the EBM proponents (EBM-ists) will produce evidence that not everybody is doing it, therefore it is not 'old hat'. (The fact that people transgress the Ten Commandments all the time doesn't make them any the less "Old hat".) The EBM-ists themselves have produced evidence that clinicians do, in fact, practise EBM without necessarily having undergone a formal baptism in the subject. This should surprise no one considering that the bedrock of scientific medicine is acting on evidence, a matter brought to the fore with the Flexner Report on Medical Education in Britain in 1926. So the EBM-ism has been around in modern medicine for some time even though the widespread use of the term, evidence-based medicine, is relatively new.
The proponents of EBM will attempt to counter my criticism that EBM is 'cook book medicine' by insisting that the best external evidence must be mixed with individual clinical expertise and patient choice, so that it cannot therefore result in slavish cook book approaches to individual patient care. I broadly agree with that, though I shall return to dangers associated with it later.
They attempt to counter my fear that EBM will be hijacked by purchasers and managers, to cut the costs of health care and shackle the profession to their will by asserting that EBM may result in expertise, efficacious interventions, rather than low-cost care, and that if EBM shows the best way of treating people, then it should be practised and that all good-thinking clinicians will go along with it, so they will not be externally shackled. Maybe, but do the managers see it like that?
DISTRUST OF MOVEMENTS
In their book Evidence-based Medicine Sackett and his colleagues2 make the following statement:
If you want to practice Evidence-based Medicine then merge it with becoming the best history-taker and clinical examiner you can be, incorporate it into becoming the most thoughtful diagnostician and therapist you can become, and consolidate it in your evolution into an effective, efficient, caring and compassionate clinician.
How can anyone disagree with such a saintly statement? Well I do not believe things are that simple and, because of that, I am cast as a heretic to be burned at the stake for putting forward opinions opposed to the orthodoxy.
However, it will become apparent that I cannot enter fully into that role because I agree that medical practice should be based upon good evidence. What I fear is an oversimplistic interpretation of EBM, a gradual and insidious inability to distinguish the policy from the slogan and the packaging, and the real issues from those emanating as institutional propaganda, particularly when they are all mixed in with a holy message, and imputations of serious wrong-doing if one strays from the straight-and-narrow. This can produce a professional straitjacket which potentially induces guilt in those who do not follow the path of righteousness.
Instinctively I distrust 'movements'. There are certain rules I apply for a happy but discontented academic life which I have learned from the writings of Bertrand Russell. 1 Never feel absolutely certain of anything 2 Never discourage thinking, for one will always succeed 3 Have little respect for the authority of others, for there are always contrary authorities to be found 4 Do not fear to be eccentric of opinion, for every opinion was once eccentric University Department of Clinical Pharmnacology, Radcliffe Infirmary, Woodstock
Road, Oxford OX2 6HE, UK 5 Find pleasure in intelligent dissent, rather than in passive agreement, for the former implies a deeper agreement than the latter 6 Do not feel envious of the happiness and contentment of those who live in a false paradise for only a fool will think it is paradise.
These attitudes govern my distrust of what I term the institutionalization of decision making in medicine. I am quite happy to give up my clinical freedom that is not the point. That battle has been lost and rightly so. But I do expect my institution, generically speaking, to trust me in the professionalism of my medical practice and not impose institutionalized decision making on me. I truly believe that there is no other sort of medicine worth practising than 'evidence-based medicine', but I am always extremely concerned whether the evidence that I am provided with is reliable, particularly if that information has been laundered by institutional forces. It takes me a long time and much reflection to accept evidence which will change my medical practice. EBM must always be the servant, not the master. Bertrand Russell said that arithmetic is a dastardly attempt to impose authority on the flux. In this context, EBM is a dastardly attempt by utilitarians to impose authority on the flux of medicine.
NO MAN IS AN ISLAND IN THE PRACTICE OF MEDICINE
Clinically, we all work within a medical culture, different geographically both within this country and internationally. Like it or not, there are fashions in medical practice which are powerful and difficult to change. Personally, I tend to be very conservative in my clinical practice, and I think that on the whole, over the years, this has borne fruit for my patients, though I have no evidence for that. Those who promote EBM have very powerful retrospectroscopes which tend to over-clarify the past. They identify mistakes made in the past, and are derisive about them. I find that rather unfair. One must go back to the medical and social environment as it was. One cannot judge yesterday's science and practice by today's knowledge and attitudes.
One must put what now appear to be mistakes in the context of their own time. Practitioners of EBM should not be impatient with their practising clinical colleagues as many of them have been misled by enthusiasms and overtaken by disasters many times in the past, as no doubt they will be in the future.
THE CONFLICT OF HEAD AND HEART IN THE PRACTICE OF EBM
On ward rounds, my heart and my head are frequently in conflict. Very often there is something about the patient's condition, some variable which often I cannot identify but which intuitively I know is there, which interferes with the simple application of current EBM. My junior staff have told me that they can spot this conflict as a fleeting expression of anguish accompanied by a disturbing sound of intellectual pain. Why does my head call me to follow the banner of EBM and my heart urge caution? * I have seen too many things come and go, lauded at first, with disillusion setting in later * So many clinical situations contain too many variables to allow me to apply without hesitation, to the case in point, the evidence culled from situations lacking those variables * Although, of course, I apply the results of population experiments to individual cases, I always do so with some apprehension, disquiet and caution. I hate flying on automatic pilot when practising medicine. This is a legacy of my long conditioning in pathology and the molecular sciences of medicine which demand from me a reductionist explanation for all my clinical actions. * I feel intuitively that clinical issues cannot yet be fully tied down by the techniques of EBM. I think that eventually this will happen but by the application of the reductionist molecular sciences.
THE UNCERTAINTIES IN MEDICAL PRACTICE
The young are very impressionable. In clinical practice they seek the confidence that EBM gives them to rid them of the element of uncertainty in clinical practice. This is the danger of the 'cook-book' approach. There are many who find it very difficult to live with the uncertainties of clinical practice. I believe that there are grave dangers in believing that you have the final answer. This is a serious risk with EBM.
There are many external pressures one faces during the practice of medicine. There are the expectations of your patient, sometimes pushing you into actions that are not in their best interests. There is the patient's need for certainty and the need for certainty of those who are inexperienced in medicine, versus your own knowledge that in any particular case, you may be in the realms of uncertainty, and whilst doing your best you are going to live with that. There is also the fear of criticism of your practice. This criticism may come from one's peers, one's seniors and juniors, and other health care staff, or from 'experts', patients and the legal profession. There are great dangers in looking over your shoulder all the time and thinking 'What would I be expected to do?' rather than 'What is the right thing to do?' I have made that mistake too many times. There are very thin lines between what is guidance, what are instructions, what are rules, and what is 'law'.
Let me illustrate some of these problems with a case history, of a patient admitted on one of my acute general medical takes. A woman of 83 was admitted to hospital with the priority referral problem of a confusional state of recent onset. She has a past medical history of generalized osteoarthritis for which, for many years, she has been receiving diclofenac as Voltarol Retard 100mg daily. She has an indistinct but plausible history of polymyalgia rheumatica for which she has been treated for a year with prednisolone, the current dose being 7.5 mg daily. For many years she has had benign asymptomatic hypertension and 2 years ago she developed mild angina on effort. Within the last 6 months she was diagnosed as having heart failure with breathlessness and oedema on the background of presumed ischaemic heart disease and hypertension. In the last 6 months she complained of palpitations and worsening of shortness of breath and was found to have atrial fibrillation. These cardiac conditions resulted in her current therapy indicating warfarin 5 mg daily (INR recently, 2.2-3), aspirin 75 mg daily, isosorbide mononitrate as Imdur 60 mg daily, glyceryltrinitrate tablets as necessary, enalapril 5 mg daily, frusemide 40mg daily, and simvastatin 1Omg daily.
Associated with the prednisolone therapy, she developed mild non-insulin dependent diabetes mellitus, unresponsive to diet, for which she receives gliclazide 80 mg daily.
Just prior to admission, she had developed a fever, cough, and become confused, and clinically a diagnosis of acute bronchitis was made. Because she was unable to look after herself at home and had no support, she was admitted to hospital. Three years previously she had suffered from a paranoid state which resulted in her taking thioridazine 50mg daily since then.
So, her drug therapy on admission was: * paracetamol two tablets three times daily * diclofenac retard 100mg daily * warfarin 5 mg daily * aspirin 75 mg daily * isosorbide mononitrate 80 mg daily * enalapril 5 mg daily * frusemide 40 mg daily * amiloride 5 mg daily * simvastatin 10 mg daily * amoxicillin 250 mg tds * gliclazide 80 mg daily * prednisolone 7.5 mg daily * thioridazine 50 mg daily When I telephoned the general practitioner (GP) to discuss the inappropriateness of all this powerful medication clear evidence base for the treatment of hypertension in the elderly and how it improves prognosis? The evidence base for the reduction of stroke by warfarin in patients with atrial fibrillation? The evidence base for simvastatin and aspirin for the prevention of myocardial infarction in patients with ischaemic heart disease? The evidence base for prednisolone in the treatment of polymyalgia rheumatica? The evidence base for the treatment of heart failure with ACE inhibitors? And that he, the GP, had received advice on each of these treatments from the specialist clinics in the local teaching hospital?
It is not the place here to write a textbook of clinical pharmacology, but this is a case where medication was getting just too complicated for the patient to take, for the patient's body to stand, and for the controlling doctor (the GP) to handle.
Among the numerous problems these treatments bring are the effects of prednisolone on the blood pressure and glucose metabolism; sodium retention caused by the diclofenac and prednisolone; hypokalaemia caused by the prednisolone and frusemide (despite the enalapril); prednisolone precipitating the raised blood glucose, i.e. diabetes mellitus; the danger of prednisolone in an 83-yearold woman of vertebral osteoporosis, possible responsible for some of the generalized osteoarthritic pain in her sacroiliac region; the risks of gastrointestinal bleeding because of diclofenac and aspirin combined with warfarin; the interaction of thioridazine with her acute septic state and dehydration; the lack of evidence that simvastatin prolongs life in someone with ischaemic heart disease who also has atrial fibrillation, benign essential hypertension and chronic failure . . . I could go on and on.
It is this sort of case, which I see frequently in my role as an on-take physician dealing with acute emergency medicine, that makes me very worried about the 'mindless' application of population studies to the treatment of the individual. I know that the specialists (though they would not like to be called that) in EBM would also throw their hands up in horror at this case. Nevertheless this is the situation that the blind application of EBM, without full cognizance of the way it should be applied, can produce.
Some reading this will ask 'Well, what did you do?' and I will tell you. We enquired carefully into the osteoarthritic pains and they did not seem so bad, and we substituted just the paracetamol two tablets three times a day for the diclofenac, and stopped the latter. We continued the warfarin as we felt that its use was justified in this woman because of her risk of embolic stroke due to atrial fibrillation, ischaemic heart disease and heart failure. We stopped the aspirin as there is no evidence to show that it prevents myocardial infarction in a patient already taking adequate doses of warfarin at the age of 83, and evidence that it does produce gastrointestinal bleeding. We in an old lady, I was upbraided: 'Didn't I know about the continued the isosorbide mononitrate and, as she did not seem to be taking the glyceryltrinitrate and had not done so for at least 6 months, we felt that was unnecessary. We continued the enalapril, and we felt it was necessary to continue the frusemide because of her symptomatic heart failure. We discontinued the simvastatin, rightly or wrongly, because we needed to simplify the therapy. We continued to treat the pneumonia with amoxicillin and within 24 h of stopping the thioridazine she became a different woman-lively, bright, mobile, humorous and 'living' again. As her erythrocyte sedimentation rate was quite normal and she had been on prednisolone for her polymyalgia rheumatica and was asymptomatic for 2 years, we instituted a tailing off of this therapy and, 6 months later when it had been discontinued, she no longer needed gliclazide for the control of her blood glucose. At follow up at 6 months, she was taking paracetamol as necessary (two to three tablets a day) and was continuing her warfarin, isosorbide moninitrate, enalapril and frusemide, and was in good spirits and health.
This case illustrates the problem of the clouding of EBM by: multiple pathology (particularly in the elderly); the influence of specialism and its sinister impact on multiple prescribing; the difficulties of applying EBM in the face of drug interactions, the incidence of which is unpredictable; and the difficulties posed by the interactions of drugs with disease. So very often, clinical trials are performed with a high degree of attention to detail and best practice which does not always apply in the hurly burly of medicine.
Of all these doubts I think that the mindless application of population results to decisions on individual management is the single factor most fraught with danger. It is this which I call 'the institutionalization of medical decision making'. I fear the dangers stemming from the attempt to excessively simplify the practice of medicine, as I also fear the institutional pressure which will be applied to doctors to go along with the latest EBM, come what may.
In 1975 a hospital drug formulary was introduced to the Oxford hospitals and a quote from the foreword, which I wrote, describes my attitude to drug prescribing and to the institutionalization of medical practice.
The general medical feeling hereabouts is that doctors should be able to prescribe what they think in good faith is necessary for the benefit of their patients, and they should not be made to feel guilty about it. There is after all no point in giving the medical profession responsibility for treatment of a disease and then denying it the means to fulfil that responsibility. But at the same time, doctors do have a duty to prescribe as rationally, as effectively, and safely, and as economically as possible. If doctors are self-critical about their use of drugs, good therapeutics will be practised and perhaps the extent of drug-induced iatrogenic disease limited. If when prescribing, they used the cheapest among therapeutically equivalent drugs, then probably, but not certainly, substantial savings will be made. Perhaps all this could be achieved by continuing education in drug use. In the long run, in the best of all possible worlds, that may be true. But the financial situation in the area is critical, and some means must be found to emphasise the cost of drugs and the importance of economic prescribing. There has been much consultation with medical staff about what should be included in this Formulary. It is hoped that clinicians will by and large be able to restrict their prescribing to drugs listed in the Formulary and if drugs outside the Formulary are prescribed, such prescribing would be a conscious clinical decision. I have to say that this now looks rather fuddy-duddy, because there is very great institutional pressure now coming from the young Turks in the New Health Service, to allow less freedom of action in prescribing.
THE PLACE OF EBM IN THE EVOLUTION OF THERAPEUTIC PRACTICE
For many years I served on the Committee on Safety of Medicines and learned much about drug development. It is instructive now to stand back and look at the course of drug development from biology through to the rough and tumble of medical practice. This is depicted in Figure 1 . In the laboratory, means are sought to manipulate a biological process through the interaction of a drug with a substrate at the molecular level. Medicinal chemistry produces a molecule to do that. Its biology is described, it is tested in animals for both its pharmacological effects and its acute and chronic toxicity. Volunteer studies are often carried out to look at the way that the body handles the drug and to describe some extent its human pharmacology. The drug then enters early clinical studies, and gradually these become more and more refined until small scale and then larger scale randomized clinical trials are carried out.
Such trials are usually rather short and involve small numbers of patients, rarely more than 2-3000 and only then for drugs which will have widespread use. If the evidence of safety and efficacy at this level reaches certain criteria, then the drug may be given a Product Licence by the Regulatory Drug Authority. It then goes on the market and may be used in complex clinical situations not envisaged during development, and trouble frequently occurs. But let us suppose that things go well and the drug seems to have a widespread application in the treatment of a common illness such as hypertension, coronary artery disease or asthma.
When the first flush of excitement has died down, science now stands back and asks just how useful and safe the drug is. This may lead to the conduct of very largescale, randomized control clinical trials in large numbers of patients, often multi-centre and usually with very simple end points. We have seen this in hypertension, coronary artery disease, and cancer. As the numbers of such trials accumulate, so the situation becomes analysable by the techniques of meta-analysis, and gradually we move into the phase of systematic reviews pioneered by the Cochrane Centre and then on to the synthesis of it all by EBM. CONCLUSION This is a new era for medical practice. EBM is very helpful in practice, even though I know from my sceptical standpoint that the theories of EBM may not always be applicable to the individual patient. EBM-ists would say that this is where my clinical expertise comes in. But it requires great expertise, experience and confidence to buck the trend of applying a treatment which has been 'blessed' by the latest EBM publication, when bucking the trend is necessary. Many doctors, particularly the more junior do not find that easy. I conclude that EBM is a very powerful and sophisticated tool for use in the practice of clinical medicine, requiring proper education in its foundations, and instruction and experience in its applications. Its wise application is not easy, and requires much consideration in the individual patient. It is certainly not a panacea for the problems of managers and public health physicians.
